Author: DOKI, Tomoyoshi; TAKANO, Tomomi; HOHDATSU, Tsutomu
Title: Development of a mouse-feline chimeric antibody against feline tumor necrosis factor-alpha Document date: 2016_6_4
ID: y0x0quha_3
Snippet: Anti-TNF-alpha agents are expected to improve the symptoms of FIP caused by viral infection. We previously described the preparation of a feline TNF-alpha (fTNF-alpha)neutralizing mouse monoclonal antibody (anti-fTNF-alpha mAb, mAb [2] [3] [4] . This mAb 2-4 exhibited high neutralizing activity against recombinant and natural TNF-alpha, and was confirmed to inhibit the following fTNF-alpha-induced conditions in vitro: i) an increase in the surviv.....
Document: Anti-TNF-alpha agents are expected to improve the symptoms of FIP caused by viral infection. We previously described the preparation of a feline TNF-alpha (fTNF-alpha)neutralizing mouse monoclonal antibody (anti-fTNF-alpha mAb, mAb [2] [3] [4] . This mAb 2-4 exhibited high neutralizing activity against recombinant and natural TNF-alpha, and was confirmed to inhibit the following fTNF-alpha-induced conditions in vitro: i) an increase in the survival rate of neutrophils from cats with FIP, ii) APN mRNA expression in macrophages and iii) apoptosis of a feline T-lymphocyte cell line [4] . These findings strongly suggested that mAb 2-4 is applicable as a therapeutic drug against FIP. We are also investigating that mouse mAb 2-4 administration to SPF cats experimentally infected with FIPV alleviated the clinical condition of cat with FIP [3] . However, because this is a mouse-derived antibody and is a xenogeneic protein for cats, induction of feline anti-mouse antibodies may reduce the reactivity of mouse mAb 2-4 against fTNF-alpha.
Search related documents:
Co phrase search for related documents- cell line and monoclonal antibody: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36
- cell line and mRNA expression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65
- cell line and neutralizing activity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- cell line and survival rate: 1, 2, 3, 4, 5, 6, 7, 8, 9
- cell line and therapeutic drug: 1, 2, 3, 4, 5, 6, 7
- cell line and tnf alpha: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- cell line and viral infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74
- clinical condition and feline anti mouse antibody: 1
- clinical condition and ftnf alpha: 1
- clinical condition and monoclonal antibody: 1, 2, 3, 4, 5
- clinical condition and neutralizing activity: 1
- clinical condition and survival rate: 1, 2, 3, 4
- clinical condition and tnf alpha: 1
- clinical condition and viral infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
- clinical condition and viral infection cause: 1
- feline anti mouse antibody and FIP therapeutic drug: 1
- feline anti mouse antibody and ftnf alpha: 1, 2, 3, 4, 5, 6, 7, 8
- feline anti mouse antibody and monoclonal antibody: 1, 2, 3
- feline anti mouse antibody and neutralizing activity: 1
Co phrase search for related documents, hyperlinks ordered by date